The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst like Andrew Fein suggests a strong vote of confidence in Foghorn Therapeutics. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in FHTX's stock price, given the analyst's influence and the specificity of the price target.